Clinical TrialMay 20, 2026, 07:02 AM
Immunovant IMVT-1402 shows 72.7% ACR20 in D2T RA trial
AI Summary
Immunovant reported positive preliminary Week 16 results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis (D2T RA), showing a 72.7% ACR20 response rate. The company also announced the discontinuation of batoclimab development across all indications to fully focus on IMVT-1402, following failed Phase 3 studies for thyroid eye disease. Immunovant ended the fiscal year with $902.1 million in cash, providing runway to the potential launch of IMVT-1402 in Graves’ disease, despite increased net losses.
Key Highlights
- IMVT-1402 D2T RA trial showed 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates at Week 16.
- Topline data for IMVT-1402 in cutaneous lupus erythematosus (CLE) expected in H2 2026.
- Discontinued batoclimab development across all indications after Phase 3 TED studies failed primary endpoint.
- Cash and cash equivalents totaled $902.1 million as of March 31, 2026.
- Q4 fiscal 2026 net loss was $147.9 million ($0.73 per common share).
- Fiscal year 2026 net loss was $505.6 million ($2.77 per common share).
- Q4 R&D expenses increased to $142.3 million, including $39.0 million for batoclimab discontinuation.
Price Impact
More from IMVT